Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...
GlobalData on MSN16d
Eli Lilly pays $10m upfront for Organovo’s FXR agonistEli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...
The company entered into a global licensing deal with South Korea’s OliX Pharmaceuticals that could be valued at up to $630 million. As per the agreement, Eli Lilly and Company (NYSE:LLY ...
Lilly’s commitment came a day after tech giant Apple announced a $500 billion commitment over the next four years to its American operations. And several automakers with factories in Alabama are ...
THE CHOSUNILBO on MSN9d
Exclusive: Vivozon Pharmaceutical seeks $17 m investment for non-opioid painkiller launchVivozon Pharmaceutical, a South Korean company specializing in the development and distribution of pharmaceutical drugs, is ...
Eli Lilly has opted to end a phase 2 rheumatoid arthritis (RA) trial of a drug it is developing with Korea’s Hanmi Pharmaceuticals, according to press reports. The Korea Biomedical Review cited ...
The global market for acute migraine treatment is on a steady growth trajectory, with sales expected to rise from USD 2,700.7 million in 2024 to USD 4,194.1 million by 2034, reflecting a CAGR of 4.5% ...
Lantheus Holdings, Inc.'s stock soars 55%, fueled by Pylarify and strategic acquisitions in Alzheimer's and oncology. Click ...
The global antidiabetics market is on a strong growth trajectory, with sales projected to soar from USD 106.3 billion in 2024 to USD 298.2 billion by 2034. This substantial increase reflects a robust ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback